RecruitingNCT07388628

ARTICE® Real Data Collection & Observational Trial, Phase 4 Study

◆ AI Clinical Summary

Plain-language summary for patients

Trial Parameters

ConditionSepsis

SponsorArtcline GmbH

Study TypeOBSERVATIONAL

PhaseN/A

Enrollment200

SexALL

Min Age18 Years

Max AgeN/A

Start Date2025-09-25

Completion2027-09

All Conditions

Sepsis Septic Shock Immunoparalysis in Septic Shock

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Your Age

Your Sex

Brief Summary

The objectives of this registry study are to: 1. Record real-life data related to the use of the ARTICE® therapy in sepsis subjects. 2. Further evaluate ARTICE® treatment efficacy. 3. Identify potential sub-groups, assess their risk-benefit- and safety profile. 4. Changes in SOFA score D0 to SOFA Score D7.

Eligibility Criteria

Inclusion Criteria: * Subjects ≥ 18 years who are planned to receive ARTICE® treatment during their ICU stay Exclusion Criteria: \-

Related Trials

NCT06178822

Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room

View Trial →

NCT03720860

Inflammatory Mediators of Acute Kidney Injury in Intensive Care

View Trial →

NCT07388628

ARTICE® Real Data Collection & Observational Trial, Phase 4 Study

View Trial →

VIEW ON CLINICALTRIALS.GOV ↗ MORE SEPSIS TRIALS